AstraZeneca

Jun 04, 2020

Gene-edited T cells for diabetes treatment The Scientists at the Seattle Children's Research Institute and the Benaroya Research Institute have got a promising finding that will turn off the destructive autoimmune response in Type 1 diabetes. This comprises editing the genes of patients' T cells. The team pre...

May 12, 2020

MyoKardia has announced the promising results of Phase III clinical trials of its lead drug mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Following the announcement, shares of the California-based company skyrocketed. The Phase III clinical trial - EXPLORER-HCM – demonstrated the pot...

May 01, 2020

Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...

Apr 22, 2020

Novel coronavirus outbreak has created some unprecedented situations in several domains round the World. No vertical is left untouched as the economy tumbles down impacting the human race. Goals of the several industries such as tourism and hospitality that are hit hard, have shifted as they find new ways to create...

Apr 09, 2020

AstraZeneca aims for summer start for COVID-19 antibody trial AstraZeneca has made its multipronged approach to the development of antibodies against the pandemic SARS-CoV-2 virus. The giant is utilizing its discovery capabilities and assisting in assessing the candidates who were identified in China and the U.S...

Feb 13, 2020

J&J collaborates with BARDA to accelerate coronavirus vaccine program Johnson & Johnson has collaborated with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to produce a vaccine against novel coronavirus. J&J is attempting to pool money and resources with BARDA in order to qu...

Jan 21, 2020

The US FDA has recently granted Orphan Drug Designation to AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC. Imfinzi, a monoclonal antibody, binds and inhibits the interaction of PD-L1 with PD-1 and CD80. The drug blocks tumour’s immune-evading mechanism and releases the inhibiti...

Nov 27, 2019

Sickle cell disease is a haematological, genetic disorder that affects millions of people worldwide. According to the NIH, “Sickle cell disease is the most common inherited blood disorder in the United States, affecting 70,000 to 80,000 Americans’’. The estimates are somewhat similar to that of CDC’s according t...

Nov 05, 2019

Amgen has announced to purchase 20.5% of the stake in Chinese-American drug company BeiGene. As per the deal signed, Amgen will develop and commercialize around two dozen of its on-market as well as experimental drug compounds for the treatment of cancer in China. The shares purchased are worth USD 2.7 bill...

Oct 15, 2019

ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells. ImaginAb is an emerging imaging company focused on immune-oncology. The technology also helps in targeting and visualizing CD8+ T cells, which are activated by the im...